| REGISTRATION |
| 09:30 - 10:00 |
Coffee and registration |
| |
|
| OPENING & WELCOME |
| 10:00 - 10:10 |
Welcome |
| |
Prof. Sybe Schaap |
| |
|
| SESSION 1: |
Plenary session - Novel developments |
| 10:15 - 11:00 |
Opportunities and Challenges for RNA vaccines and therapeutics |
| |
Prof. Robin Shattock - Department of Infectious Disease, Imperial College London |
| 11:00 - 11:45 |
Opportunities and Challenges for virus-based therapeutics in humans |
| |
Prof. Ron Fouchier - Department of Viroscience, Erasmus Medical Center |
| |
|
| 11:45 - 13:15 |
Lunch |
| |
|
| SESSION 2: |
Clinical and veterinary therapeutics |
| 13:15 - 13:45 |
First-in-human clinical trial with an alphavirus-based replicon vaccine against HPV-induced cancers |
| |
Prof. Toos Daemen - Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen |
| 13:45 - 14:15 |
Vaccine platform technologies within Animal Health – Possibilities and limitations |
| |
Dr. Martijn Langereis - MSD Animal Health |
| |
|
| SESSION 3: |
Biosafety aspects |
| 14:15 - 14:45 |
Viral replicon systems and their biosafety aspects - Inventory and description of viral replicon systems and characteristics relevant for risk assessment |
| |
Dr. Karen van der Meulen - Perseus B.V. |
| 14:45 - 15:15 |
Rise of the RNA machines - self-amplification as next step in mRNA vaccine design |
| |
Dr. Gorben Pijlman - Laboratory of Virology, Wageningen University |
| |
|
| 15:15 - 15:45 |
Coffee Break |
| |
|
| SESSION 4: |
Considerations for regulation |
| 15:45 - 16:05 |
Clinical studies with GMOs in the Netherlands: Regulations in a rapidly emerging field |
| |
Dr. Marco Gielkens - GMO office, National Institute for Public Health and the Environment |
| 16:05 - 16:25 |
Biological containment and the UK regulatory approach to Contained Use and Deliberate Release of GM vaccines |
| |
Dr. Sean Simpkins - Department for Environment Food and Rural Affairs |
| 16:25 - 16:45 |
To be announced |
| 16:45 - 17:15 |
Discussion on future proof regulation |
| |
| CONCLUDING REMARKS |
| 17:15 - 17:25 |
Concluding remarks |
